Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bitcoinruson Mar 20, 2018 9:45pm

76 Views

Post# 27750683

RE:RE:RE:RE:WOMAC # higher for ATB346 than Naproxen

You're denser than Hilliary." In this trial, a once daily dose of ATB-346 produced a reduction of the WOMAC pain score of 4.3 units on day 4, increasing to 7.6 units on day 10.

Annnnnnnnnnd,Naproxen remained at 4.0. Which is,but hey,don't hold me to it,less than 7.6. So it sure looks like the dose of ATb346 will have to be increased to attain the same WOMAC score as Naproxen. Maybe,just maybe that's why they are making them do an efficacy trial????

ltrcola wrote: Literally don't know why I'm reply to this...

How about we try this again - this time right from the NR:

“There is a large body of evidence showing that market-leading arthritis drugs like celecoxib and naproxen, taken twice daily for a week or more, typically reduce WOMAC pain scores by ~4 units, with no material improvement beyond that level with continued treatment,” remarked John Wallace, Antibe’s Chief Scientific Officer. “In this trial, a once daily dose of ATB-346 produced a reduction of the WOMAC pain score of 4.3 units on day 4, increasing to 7.6 units on day 10

bitcoinrus wrote:
How about an unbiased site like The American College of Rheumatology which descibes how the WOMAC scale works. Have someone read it to you.

Interpretation of Scores

Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

Atb346 scores a 7 where Naproxen scores a 4.

To help you along, 7 is greater than 4.

https://www.rheumatology.org/I-Am-A/Rheumatologist/Research/Clinician-Researchers/Western-Ontario-McMaster-Universities-Osteoarthritis-Index-WOMAC

Chrisperrierceo wrote: How about you do any research before making such uneducated comments. Let John Wallce tell you why you're wrong
https://youtu.be/w_3heP7ol0A?t=23m10s